{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:03:46Z","timestamp":1791515026695,"version":"4.3.4"},"reference-count":115,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. The limited expression of MSLN in normal tissues (peritoneum, pleura and pericardium) and its overexpression in 80 to 90% of PDAC make it an attractive candidate for therapeutic management of PDAC patients. Moreover, its role in malignant progression related to its involvement in tumor cell proliferation and resistance to chemotherapy has highlighted the relevance of its targeting. Hence, several clinical trials are investigating anti-MSLN efficacy in PDAC. In this review, we provide a general overview of the different roles sustained by MSLN during PDAC progression. Finally, we also summarize the different MSLN-targeted therapies that are currently tested in the clinic.<\/jats:p>","DOI":"10.3390\/ijms21114067","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T05:16:14Z","timestamp":1591679774000},"page":"4067","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-1812","authenticated-orcid":false,"given":"Christopher","family":"Montemagno","sequence":"first","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco"},{"name":"Institute for Research on Cancer and Aging of Nice, Universit\u00e9 Cote d\u2019Azur, CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, 06200 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir","family":"Cassim","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2779-6902","authenticated-orcid":false,"given":"Jacques","family":"Pouyssegur","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco"},{"name":"Institute for Research on Cancer and Aging of Nice, Universit\u00e9 Cote d\u2019Azur, CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, 06200 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4265-8463","authenticated-orcid":false,"given":"Alexis","family":"Broisat","sequence":"additional","affiliation":[{"name":"Laboratoire Radiopharmaceutiques Biocliniques, INSERM, 1039-Universit\u00e9 de Grenoble, 38700 La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8466-5610","authenticated-orcid":false,"given":"Gilles","family":"Pag\u00e8s","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie M\u00e9dicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco"},{"name":"Institute for Research on Cancer and Aging of Nice, Universit\u00e9 Cote d\u2019Azur, CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, 06200 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/cam4.767","article-title":"Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030","volume":"5","author":"Quante","year":"2016","journal-title":"Cancer Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2017.12.004","article-title":"Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells","volume":"415","author":"Rahn","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cmet.2015.12.015","article-title":"Obesity and Cancer: The Oil that Feeds the Flame","volume":"23","author":"Sun","year":"2016","journal-title":"Cell Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1158\/1078-0432.CCR-15-1256","article-title":"Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment","volume":"22","author":"Delitto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.1038\/s41598-017-08794-1","article-title":"Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73240","DOI":"10.18632\/oncotarget.17291","article-title":"Germline mutations in pancreatic cancer and potential new therapeutic options","volume":"8","author":"Pihlak","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.21873\/anticanres.13026","article-title":"Targeted Therapies for Pancreatic Cancer and Hurdles Ahead","volume":"38","author":"Aslan","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-16-2319","article-title":"Current and Emerging Therapies in Metastatic Pancreatic Cancer","volume":"23","author":"Manji","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_15","first-page":"1","article-title":"Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club","volume":"14","author":"Winter","year":"2019","journal-title":"Prz. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3748\/wjg.v24.i20.2137","article-title":"Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?","volume":"24","author":"Hilmi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I Study of Pembrolizumab (MK-3475; Anti\u2013PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11523-018-0567-0","article-title":"The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review","volume":"13","author":"Nichetti","year":"2018","journal-title":"Target Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sathyanarayana, B.K., Hahn, Y., Patankar, M.S., Pastan, I., and Lee, B. (2009). Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. BMC Struct. Biol., 9.","DOI":"10.1186\/1472-6807-9-1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1096\/fj.14-257352","article-title":"MUC16: Molecular analysis and its functional implications in benign and malignant conditions","volume":"28","author":"Haridas","year":"2014","journal-title":"FASEB J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1172\/JCI88845","article-title":"Mesothelin\/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Invest."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.18632\/genesandcancer.104","article-title":"MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism","volume":"7","author":"Muniyan","year":"2016","journal-title":"Genes Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2018.1418326","article-title":"Peritoneal dissemination of ovarian cancer: Role of MUC16-mesothelin interaction and implications for treatment","volume":"18","author":"Coelho","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_35","first-page":"181","article-title":"Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium","volume":"52","author":"Chang","year":"1992","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tozbikian, G., Brogi, E., Kadota, K., Catalano, J., Akram, M., Patil, S., Ho, A.Y., Reis-Filho, J.S., Weigelt, B., and Norton, L. (2014). Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114900"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14737140.2016.1192472","article-title":"Should anti-mesothelin therapies be explored in lung cancer?","volume":"16","author":"Thomas","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sahni, S., Moon, E.A., Howell, V.M., Mehta, S., Pavlakis, N., Chan, D., Ahadi, M.S., Gill, A.J., Samra, J., and Mittal, A. (2020). Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Eur. J Surg. Oncol.","DOI":"10.1016\/j.ejso.2020.02.001"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejso.2018.10.050","article-title":"Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study","volume":"45","author":"Nahm","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_42","first-page":"2476","article-title":"Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma","volume":"6","author":"Sopha","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Montemagno, C., Cassim, S., Trichanh, D., Savary, C., Pouyssegur, J., Pag\u00e8s, G., Fagret, D., Broisat, A., and Ghezzi, C. (2019). 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma. Cancers, 11.","DOI":"10.3390\/cancers11101531"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3","volume":"6","author":"Bharadwaj","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wang, K., Bodempudi, V., Liu, Z., Borrego-Diaz, E., Yamoutpoor, F., Meyer, A., Woo, R.A., Pan, W., Dudek, A.Z., and Olyaee, M.S. (2012). Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033214"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1756-9966-31-84","article-title":"Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway","volume":"31","author":"Zheng","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","article-title":"Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells","volume":"6","author":"Uehara","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1349-7006.2012.02214.x","article-title":"Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma","volume":"103","author":"Shimizu","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_53","first-page":"1","article-title":"Mesothelin Binding to CA125\/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Invest."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","article-title":"Epithelial Mesenchymal Transition in Tumor Metastasis","volume":"13","author":"Mittal","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"He, X., Wang, L., Riedel, H., Wang, K., Yang, Y., Dinu, C.Z., and Rojanasakul, Y. (2017). Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol. Cancer, 16.","DOI":"10.1186\/s12943-017-0633-8"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Avula, L.R., Rudloff, M., El-Behaedi, S., Arons, D., Albalawy, R., Chen, X., Zhang, X., and Alewine, C. (2019). Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases. Mol. Cancer Res.","DOI":"10.1158\/1541-7786.MCR-19-0688"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Melaiu, O., Stebbing, J., Lombardo, Y., Bracci, E., Uehara, N., Bonotti, A., Cristaudo, A., Foddis, R., Mutti, L., and Barale, R. (2014). MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085935"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1074\/jbc.M110.193458","article-title":"Structural Analysis of the Cancer-specific Promoter in Mesothelin and in Other Genes Overexpressed in Cancers","volume":"286","author":"Ren","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"De Santi, C., Vencken, S., Blake, J., Haase, B., Benes, V., Gemignani, F., Landi, S., and Greene, C.M. (2017). Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170999"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-12-3776","article-title":"A Tumorigenic Factor Interactome Connected Through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer","volume":"19","author":"Li","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00404-013-3128-x","article-title":"Serum soluble mesothelin-related peptide (SMRP): A potential diagnostic and monitoring marker for epithelial ovarian cancer","volume":"289","author":"Wu","year":"2014","journal-title":"Arch. Gynecol. Obs."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.lungcan.2005.03.020","article-title":"Soluble mesothelin-related protein\u2014A blood test for mesothelioma","volume":"49","author":"Robinson","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: A potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/cclm.2011.816","article-title":"Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers","volume":"50","author":"Sharon","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<559::AID-IJC13>3.0.CO;2-Y","article-title":"111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin","volume":"80","author":"Hassan","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kobayashi, K., Sasaki, T., Takenaka, F., Yakushiji, H., Fujii, Y., Kishi, Y., Kita, S., Shen, L., Kumon, H., and Matsuura, E. (2015). A Novel PET Imaging Using 64Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells. J. Immunol. Res., 2015.","DOI":"10.1155\/2015\/268172"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42081","DOI":"10.18632\/oncotarget.5877","article-title":"Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts","volume":"6","author":"Kosterink","year":"2015","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1535-7163.MCT-16-0449","article-title":"Preclinical Efficacy of an Antibody\u2013Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET","volume":"16","author":"Ogasawara","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","article-title":"ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment","volume":"22","author":"Lamberts","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.18632\/oncotarget.2883","article-title":"Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging","volume":"6","author":"Lindenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1111\/cas.14150","article-title":"Novel single-chain variant of antibody against mesothelin established by phage library","volume":"110","author":"Yakushiji","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"Ho","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-06-0441","article-title":"Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-11-0493","article-title":"Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts","volume":"17","author":"Mossoba","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Hollevoet","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9189","DOI":"10.18632\/oncotarget.13984","article-title":"Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes","volume":"8","author":"Kolyvas","year":"2017","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"87307","DOI":"10.18632\/oncotarget.20263","article-title":"Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_85","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"33844","DOI":"10.18632\/oncotarget.26117","article-title":"The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model","volume":"9","author":"Mizukami","year":"2018","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00280-016-2984-z","article-title":"Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection","volume":"77","author":"Gupta","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hassan, R., Blumenschein, G.R., Moore, K.N., Santin, A.D., Kindler, H.L., Nemunaitis, J.J., Seward, S.M., Thomas, A., Kim, S.K., and Rajagopalan, P. (2020). First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J. Clin. Oncol., JCO1902085.","DOI":"10.1200\/JCO.19.02085"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models","volume":"13","author":"Scales","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"B057","DOI":"10.1158\/1535-7163.TARG-19-B057","article-title":"Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors","volume":"18","author":"Clarke","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Targeted Alpha Therapy Working Group, Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Lind\u00e9n, O., Noordzij, W., Park, J., and Saad, F. (2018). Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncol., 4, 1765\u20131772.","DOI":"10.1001\/jamaoncol.2018.4044"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2967\/jnumed.118.223701","article-title":"Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models","volume":"60","author":"Wickstroem","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","article-title":"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation","volume":"253","author":"Lutz","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A Live-attenuated Listeria Vaccine (ANZ-100) and a Live-attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase 1 Studies of Safety and Immune Induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)","volume":"25","author":"Le","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/gt.2015.85","article-title":"Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator","volume":"23","author":"Chang","year":"2016","journal-title":"Gene Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"31448","DOI":"10.18632\/oncotarget.25837","article-title":"Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope peptide derived from mesothelin in pancreatic cancer","volume":"9","author":"Tsukagoshi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Tsujikawa, T., Crocenzi, T., Durham, J.N., Sugar, E.A., Wu, A.A., Onners, B., Nauroth, J.M., Anders, R.A., Fertig, E.J., and Laheru, D.A. (2020). Evaluation of Cyclophosphamide\/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-19-3978"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Qin, L., Zhao, R., and Li, P. (2017). Incorporation of functional elements enhances the antitumor capacity of CAR T cells. Exp. Hematol. Oncol., 6.","DOI":"10.1186\/s40164-017-0088-z"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","article-title":"T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma","volume":"28","author":"Stromnes","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2018.04.007","article-title":"Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer","volume":"329","author":"He","year":"2018","journal-title":"Cell. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"13694","DOI":"10.18632\/oncotarget.24122","article-title":"Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/4067\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:36:15Z","timestamp":1760175375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/4067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":115,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21114067"],"URL":"https:\/\/doi.org\/10.3390\/ijms21114067","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]}}}